Chongqing Huapont Pharmaceutical Co., Ltd.
Chongqing Huapont Pharmaceutical, Co, Ltd established in 1992, is a listed pharmaceutical company (stock code: 002004) manufacturing and marketing APIs as well as finished dosages to the domestic and international market.
Huapont is the leading pharmaceutical company specializing in dermatology in China, accounting for about 60% market share of China retinoic acids market, one of which, acitretin, has got GMP and COS approved. (R0-CEP 2005-226-Rev 00)
Huapont is comprised of a R&D center, two dosage form facilities and three API facilities. there are over 120 employees in the R&D center, most of whom have the college degree or higher. In addition, Shaanxi Hanjiang Pharmaceutical,Co, Ltd (acquired by Huapont in 2005), one of the three API facilities, is the API Exporting base for Huapont. It is an US-cGMP compliant pharmaceutical enterprise, which is not only COS acquired for several products, but also US-FDA inspected and approved. It has been an API supplier for Janssen Pharmaceutical Belgium for more than 20 years, Our customers think highly of us for sufficiently protecting for their intellectual property and commercial benefits during the whole course of our cooperation.
Custom manufacture is an important business for Huapont, We can offer a wide range of products and services to companies involved in pharmaceutical, veterinary, nutraceutical, cosmetic, specialty chemicals, and other industries. And our resources are ready to deal with such items as designing, developing and optimizing synthetic routes, producing and/or scaling up intermediates and APIs, process development, process validation, or commercial manufacturing for you.